主动脉瓣狭窄患者的腔内植入术。

Konstantinos P Toutouzas, Konstantinos E Stathogiannis, George S Latsios, Andreas G Synetos, Christodoulos I Stefanadis
{"title":"主动脉瓣狭窄患者的腔内植入术。","authors":"Konstantinos P Toutouzas,&nbsp;Konstantinos E Stathogiannis,&nbsp;George S Latsios,&nbsp;Andreas G Synetos,&nbsp;Christodoulos I Stefanadis","doi":"10.2174/157489012803832766","DOIUrl":null,"url":null,"abstract":"<p><p>Aortic valve stenosis is becoming a burden to society due to the constantly aging population. After the onset of the first symptoms it usually follows an ominous route with high mortality levels even at two years without any medical intervention. The gold standard for treating aortic valve stenosis is surgical replacement; nonetheless, 30% of patients are left untreated due to increased risk of surgery. A less invasive method has been developed in the past decade, transcatheter aortic valve implantation (TAVI), which allows implantation of prosthesis in the native stenosed aortic valve position, using a catheter that enters the body in a transvascular way or through a minimal surgical cut down. In this review, we briefly discuss where the TAVI field begun, focus on the recent valves that are being used and finally look at what lies ahead. The review of the patents will assist in the understanding of how this field evolved, how it became established and what is to be expected in the future.</p>","PeriodicalId":20905,"journal":{"name":"Recent patents on cardiovascular drug discovery","volume":"7 3","pages":"206-15"},"PeriodicalIF":0.0000,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/157489012803832766","citationCount":"5","resultStr":"{\"title\":\"Recent valves used for transluminal implantation in patients with aortic valve stenosis.\",\"authors\":\"Konstantinos P Toutouzas,&nbsp;Konstantinos E Stathogiannis,&nbsp;George S Latsios,&nbsp;Andreas G Synetos,&nbsp;Christodoulos I Stefanadis\",\"doi\":\"10.2174/157489012803832766\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Aortic valve stenosis is becoming a burden to society due to the constantly aging population. After the onset of the first symptoms it usually follows an ominous route with high mortality levels even at two years without any medical intervention. The gold standard for treating aortic valve stenosis is surgical replacement; nonetheless, 30% of patients are left untreated due to increased risk of surgery. A less invasive method has been developed in the past decade, transcatheter aortic valve implantation (TAVI), which allows implantation of prosthesis in the native stenosed aortic valve position, using a catheter that enters the body in a transvascular way or through a minimal surgical cut down. In this review, we briefly discuss where the TAVI field begun, focus on the recent valves that are being used and finally look at what lies ahead. The review of the patents will assist in the understanding of how this field evolved, how it became established and what is to be expected in the future.</p>\",\"PeriodicalId\":20905,\"journal\":{\"name\":\"Recent patents on cardiovascular drug discovery\",\"volume\":\"7 3\",\"pages\":\"206-15\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2174/157489012803832766\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent patents on cardiovascular drug discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/157489012803832766\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on cardiovascular drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/157489012803832766","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

摘要

随着人口老龄化的不断加剧,主动脉瓣狭窄日益成为社会的负担。在最初症状出现后,通常会出现不祥的发展趋势,即使在没有任何医疗干预的情况下,两年后的死亡率也很高。治疗主动脉瓣狭窄的金标准是手术置换;然而,由于手术风险增加,30%的患者没有得到治疗。在过去的十年里,一种侵入性较小的方法被开发出来,即经导管主动脉瓣植入术(TAVI),它允许在原有狭窄的主动脉瓣位置植入假体,使用导管通过经血管的方式进入体内或通过最小的手术切口。在本文中,我们简要讨论了TAVI油田的起源,重点介绍了最近使用的阀门,最后展望了未来的发展方向。对专利的审查将有助于了解该领域是如何发展的,它是如何建立起来的,以及未来的预期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Recent valves used for transluminal implantation in patients with aortic valve stenosis.

Aortic valve stenosis is becoming a burden to society due to the constantly aging population. After the onset of the first symptoms it usually follows an ominous route with high mortality levels even at two years without any medical intervention. The gold standard for treating aortic valve stenosis is surgical replacement; nonetheless, 30% of patients are left untreated due to increased risk of surgery. A less invasive method has been developed in the past decade, transcatheter aortic valve implantation (TAVI), which allows implantation of prosthesis in the native stenosed aortic valve position, using a catheter that enters the body in a transvascular way or through a minimal surgical cut down. In this review, we briefly discuss where the TAVI field begun, focus on the recent valves that are being used and finally look at what lies ahead. The review of the patents will assist in the understanding of how this field evolved, how it became established and what is to be expected in the future.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Patents and Heart Valve Surgery - III: Percutaneous Heart Valves. Patents and Heart Valve Surgery - III: Percutaneous Heart Valves. New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel. Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy? Ticagrelor: a novel drug for an old problem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1